Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer
Breast Neoplasms
DRUG: SU014813
To determine the antitumor efficacy of single agent SU-014813 at a dose of 100 mg orally once daily in patients with MBC, June 2008
To assess onset and duration of tumor control and 1-year survival rate, AUG 2008|To evaluate the safety of SU-014813To assess patient reported outcomes, AUG 2008|To determine SU-014813 plasma trough concentration (Ctrough), AUG 2008|To explore the relationship between Ctrough and efficacy, safety, and biomarkers, AUG 2008|To explore the correlations of cancer biomarkers with treatment-related outcomes, AUG 2008
To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer